These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

738 related articles for article (PubMed ID: 19567655)

  • 21. Incidence of left ventricular function improvement after primary prevention ICD implantation for non-ischaemic dilated cardiomyopathy: a multicentre experience.
    Verma A; Wulffhart Z; Lakkireddy D; Khaykin Y; Kaplan A; Sarak B; Biria M; Pillarisetti J; Bhat P; Di Biase L; Constantini O; Quan K; Natale A
    Heart; 2010 Apr; 96(7):510-5. PubMed ID: 19884110
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Death without prior appropriate implantable cardioverter-defibrillator therapy: a competing risk study.
    Koller MT; Schaer B; Wolbers M; Sticherling C; Bucher HC; Osswald S
    Circulation; 2008 Apr; 117(15):1918-26. PubMed ID: 18391108
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effectiveness of implantable defibrillators in octogenarians and nonagenarians for primary prevention of sudden cardiac death.
    Mezu U; Adelstein E; Jain S; Saba S
    Am J Cardiol; 2011 Sep; 108(5):718-22. PubMed ID: 21640321
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Indications and outcome of implantable cardioverter-defibrillators for primary and secondary prophylaxis in patients with noncompaction cardiomyopathy.
    Caliskan K; Szili-Torok T; Theuns DA; Kardos A; Geleijnse ML; Balk AH; van Domburg RT; Jordaens L; Simoons ML
    J Cardiovasc Electrophysiol; 2011 Aug; 22(8):898-904. PubMed ID: 21332865
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term follow-up of primary and secondary prevention implantable cardioverter defibrillator patients.
    van Welsenes GH; van Rees JB; Borleffs CJ; Cannegieter SC; Bax JJ; van Erven L; Schalij MJ
    Europace; 2011 Mar; 13(3):389-94. PubMed ID: 21208947
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ventricular arrhythmias among implantable cardioverter-defibrillator recipients for primary prevention: impact of chronic total coronary occlusion (VACTO Primary Study).
    Nombela-Franco L; Mitroi CD; Fernández-Lozano I; García-Touchard A; Toquero J; Castro-Urda V; Fernández-Diaz JA; Perez-Pereira E; Beltrán-Correas P; Segovia J; Werner GS; Javier G; Luis AP
    Circ Arrhythm Electrophysiol; 2012 Feb; 5(1):147-54. PubMed ID: 22205684
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Causes and consequences of heart failure after prophylactic implantation of a defibrillator in the multicenter automatic defibrillator implantation trial II.
    Goldenberg I; Moss AJ; Hall WJ; McNitt S; Zareba W; Andrews ML; Cannom DS;
    Circulation; 2006 Jun; 113(24):2810-7. PubMed ID: 16769917
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recurrence of ventricular arrhythmias in ischaemic secondary prevention implantable cardioverter defibrillator recipients: long-term follow-up of the Leiden out-of-hospital cardiac arrest study (LOHCAT).
    Borleffs CJ; van Erven L; Schotman M; Boersma E; Kiès P; van der Burg AE; Zeppenfeld K; Bootsma M; van der Wall EE; Bax JJ; Schalij MJ
    Eur Heart J; 2009 Jul; 30(13):1621-6. PubMed ID: 19493865
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effectiveness of implantable cardioverter-defibrillators for the primary prevention of sudden cardiac death in women with advanced heart failure: a meta-analysis of randomized controlled trials.
    Ghanbari H; Dalloul G; Hasan R; Daccarett M; Saba S; David S; Machado C
    Arch Intern Med; 2009 Sep; 169(16):1500-6. PubMed ID: 19752408
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Implantable cardioverter defibrillator therapy for prevention of sudden cardiac death in children in the Netherlands.
    Heersche JH; Blom NA; van de Heuvel F; Blank C; Reimer AG; Clur SA; Witsenburg M; ten Harkel AD
    Pacing Clin Electrophysiol; 2010 Feb; 33(2):179-85. PubMed ID: 20025697
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Use of implantable cardioverter defibrillators for primary prevention in the community: do women and men equally meet trial enrollment criteria?
    Daugherty SL; Peterson PN; Wang Y; Curtis JP; Heidenreich PA; Lindenfeld J; Vidaillet HJ; Masoudi FA;
    Am Heart J; 2009 Aug; 158(2):224-9. PubMed ID: 19619698
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hospital variation and characteristics of implantable cardioverter-defibrillator use in patients with heart failure: data from the GWTG-HF (Get With The Guidelines-Heart Failure) registry.
    Shah B; Hernandez AF; Liang L; Al-Khatib SM; Yancy CW; Fonarow GC; Peterson ED;
    J Am Coll Cardiol; 2009 Feb; 53(5):416-22. PubMed ID: 19179199
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognosis among survivors of primary ventricular fibrillation in the percutaneous coronary intervention era.
    de Jong JS; Marsman RF; Henriques JP; Koch KT; de Winter RJ; Tanck MW; Wilde AA; Dekker LR
    Am Heart J; 2009 Sep; 158(3):467-72. PubMed ID: 19699872
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sudden death and defibrillators in transposition of the great arteries with intra-atrial baffles: a multicenter study.
    Khairy P; Harris L; Landzberg MJ; Fernandes SM; Barlow A; Mercier LA; Viswanathan S; Chetaille P; Gordon E; Dore A; Cecchin F
    Circ Arrhythm Electrophysiol; 2008 Oct; 1(4):250-7. PubMed ID: 19808416
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Influence of gender on ICD implantation for primary and secondary prevention of sudden cardiac death.
    Davis DR; Tang AS; Lemery R; Green MS; Gollob MH; Birnie DH
    Europace; 2006 Dec; 8(12):1054-6. PubMed ID: 17101630
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost of preimplantation cardiac imaging in patients referred for a primary-prevention implantable cardioverter-defibrillator.
    Krahn AD; Hoch JS; Rockx MA; Leong-Sit P; Gula LJ; Yee R; Skanes AC; Klein GJ
    Am J Cardiol; 2008 Sep; 102(5):588-92. PubMed ID: 18721517
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rates and predictors of appropriate implantable cardioverter-defibrillator therapy delivery: results from the EVADEF cohort study.
    Otmani A; Trinquart L; Marijon E; Lavergne T; Waintraub X; Lepillier A; Chatellier G; Le Heuzey JY;
    Am Heart J; 2009 Aug; 158(2):230-237.e1. PubMed ID: 19619699
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The ABCD (Alternans Before Cardioverter Defibrillator) Trial: strategies using T-wave alternans to improve efficiency of sudden cardiac death prevention.
    Costantini O; Hohnloser SH; Kirk MM; Lerman BB; Baker JH; Sethuraman B; Dettmer MM; Rosenbaum DS;
    J Am Coll Cardiol; 2009 Feb; 53(6):471-9. PubMed ID: 19195603
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of medical therapy for the reduction of heart failure events in patients with implanted cardioverter defibrillators.
    Pietrasik G; Goldenberg I; McNitt S; Polonsky B; Moss AJ; Zareba W
    J Cardiovasc Electrophysiol; 2009 Apr; 20(4):395-400. PubMed ID: 19017351
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of the main implantable cardioverter-defibrillator trials in clinical practice: data from the Italian ICD Registry for the years 2005-07.
    Proclemer A; Ghidina M; Gregori D; Facchin D; Rebellato L; Fioretti P; Brignole M
    Europace; 2009 Apr; 11(4):465-75. PubMed ID: 19136490
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 37.